Cargando…
Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
Background: The role of neoadjuvant chemotherapy (NAC) in the prognosis of breast cancer among patients with grade 2 tumors remains unclear. As such, we aimed to explore the relationships between NAC and survival outcomes among patients with grade 2 breast cancer. Materials and Methods: We collected...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843887/ https://www.ncbi.nlm.nih.gov/pubmed/31737103 http://dx.doi.org/10.7150/jca.33168 |
_version_ | 1783468321782366208 |
---|---|
author | Zhu, Xudong Xue, Jinqi Gu, Xi Chen, Guanglei Cao, Fangning Shan, Huilian Wang, Dan Qiao, Xinbo Liu, Caigang Zhang, Yixiao |
author_facet | Zhu, Xudong Xue, Jinqi Gu, Xi Chen, Guanglei Cao, Fangning Shan, Huilian Wang, Dan Qiao, Xinbo Liu, Caigang Zhang, Yixiao |
author_sort | Zhu, Xudong |
collection | PubMed |
description | Background: The role of neoadjuvant chemotherapy (NAC) in the prognosis of breast cancer among patients with grade 2 tumors remains unclear. As such, we aimed to explore the relationships between NAC and survival outcomes among patients with grade 2 breast cancer. Materials and Methods: We collected data on 726 breast cancer patients with grade 2 tumors and at least 5-years of follow-up from the date of diagnosis. We then conducted survival analyses to examine the association between NAC and disease-free survival (DFS) and overall survival (OS). The role of NAC in prognosis was further examined in subgroup analyses, with patients stratified according to molecular subtypes, histological grade, ER status, PR status, HER2 status and Ki67 index. We also determined the main sites of local recurrence, as well as these organs involved in distant metastasis among patients receiving NAC. Finally, we analyzed independent predictive factors for DFS and OS using Cox regression analyses. Results: Among patients who received NAC, the prevalence of pathologic complete response (pCR) was 9.87% (23/233), with 32.6% of patients (76/233) experiencing partial response. Survival analyses demonstrated that NAC had an overall adverse effect on DFS and OS. Subgroup analyses showed that patients who received NAC had shorter DFS in all molecular subgroups of breast cancer, with exception of triple negative breast cancer (TNBC) patients. NAC was also associated with shorter OS among patients with histological grade of 2 and a low Ki67 index. The main recurrence site was the chest well, while distant metastasis occurred in the bone, liver and lung. In Cox regression analyses, we found that NAC was an independent predictor for DFS, but not for OS. Conclusions: NAC may have an adverse effect on breast cancer prognosis among patients with grade 2 tumors. These patients need not receive NAC, except when the patient has a strong desire for breast conservation, and this is unlikely to be achieved in the absence of NAC. |
format | Online Article Text |
id | pubmed-6843887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-68438872019-11-15 Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer Zhu, Xudong Xue, Jinqi Gu, Xi Chen, Guanglei Cao, Fangning Shan, Huilian Wang, Dan Qiao, Xinbo Liu, Caigang Zhang, Yixiao J Cancer Research Paper Background: The role of neoadjuvant chemotherapy (NAC) in the prognosis of breast cancer among patients with grade 2 tumors remains unclear. As such, we aimed to explore the relationships between NAC and survival outcomes among patients with grade 2 breast cancer. Materials and Methods: We collected data on 726 breast cancer patients with grade 2 tumors and at least 5-years of follow-up from the date of diagnosis. We then conducted survival analyses to examine the association between NAC and disease-free survival (DFS) and overall survival (OS). The role of NAC in prognosis was further examined in subgroup analyses, with patients stratified according to molecular subtypes, histological grade, ER status, PR status, HER2 status and Ki67 index. We also determined the main sites of local recurrence, as well as these organs involved in distant metastasis among patients receiving NAC. Finally, we analyzed independent predictive factors for DFS and OS using Cox regression analyses. Results: Among patients who received NAC, the prevalence of pathologic complete response (pCR) was 9.87% (23/233), with 32.6% of patients (76/233) experiencing partial response. Survival analyses demonstrated that NAC had an overall adverse effect on DFS and OS. Subgroup analyses showed that patients who received NAC had shorter DFS in all molecular subgroups of breast cancer, with exception of triple negative breast cancer (TNBC) patients. NAC was also associated with shorter OS among patients with histological grade of 2 and a low Ki67 index. The main recurrence site was the chest well, while distant metastasis occurred in the bone, liver and lung. In Cox regression analyses, we found that NAC was an independent predictor for DFS, but not for OS. Conclusions: NAC may have an adverse effect on breast cancer prognosis among patients with grade 2 tumors. These patients need not receive NAC, except when the patient has a strong desire for breast conservation, and this is unlikely to be achieved in the absence of NAC. Ivyspring International Publisher 2019-09-07 /pmc/articles/PMC6843887/ /pubmed/31737103 http://dx.doi.org/10.7150/jca.33168 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Zhu, Xudong Xue, Jinqi Gu, Xi Chen, Guanglei Cao, Fangning Shan, Huilian Wang, Dan Qiao, Xinbo Liu, Caigang Zhang, Yixiao Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer |
title | Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer |
title_full | Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer |
title_fullStr | Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer |
title_full_unstemmed | Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer |
title_short | Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer |
title_sort | neoadjuvant chemotherapy plays an adverse role in the prognosis of grade 2 breast cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843887/ https://www.ncbi.nlm.nih.gov/pubmed/31737103 http://dx.doi.org/10.7150/jca.33168 |
work_keys_str_mv | AT zhuxudong neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT xuejinqi neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT guxi neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT chenguanglei neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT caofangning neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT shanhuilian neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT wangdan neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT qiaoxinbo neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT liucaigang neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer AT zhangyixiao neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer |